Clinical trial
A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma
NCT00502307 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- August 31, 2010
- Enrollment
- 272 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.